Almirall SA Share Price CBOE EUROPE EQUITIES
Equities
ES0157097017
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
10/06 | Almirall: extension of indication in actinic keratosis | CF |
10/06 | Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area | MT |
Sales 2024 * | 975M 1.04B 87.16B | Sales 2025 * | 1.08B 1.16B 96.81B | Capitalization | 2.06B 2.21B 185B |
---|---|---|---|---|---|
Net income 2024 * | 21M 22.48M 1.88B | Net income 2025 * | 57M 61M 5.1B | EV / Sales 2024 * | 2.14 x |
Net Debt 2024 * | 17.76M 19.01M 1.59B | Net cash position 2025 * | 73.5M 78.66M 6.57B | EV / Sales 2025 * | 1.84 x |
P/E ratio 2024 * |
93.9
x | P/E ratio 2025 * |
36.2
x | Employees | - |
Yield 2024 * |
1.59% | Yield 2025 * |
1.81% | Free-Float | 36.02% |
Latest transcript on Almirall SA
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 25/14/25 | |
Director of Finance/CFO | 54 | 11/19/11 | |
Karl Ziegelbauer
CTO | Chief Tech/Sci/R&D Officer | - | 07/21/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth J. Orlow
BRD | Director/Board Member | - | 01/16/01 |
Eva-Lotta Allan
BRD | Director/Board Member | 65 | 01/20/01 |
Director/Board Member | 65 | 01/19/01 |
1st Jan change | Capi. | |
---|---|---|
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |